WINDLASWindlas Biotech Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 0.8 this quarter.
Momentum from moving averages, Supertrend and RSI.
3 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
3 found · risk elevated
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹264 Cr | ₹18 Cr | 8.25% | 6.84% | ₹8.75 | 11.0x |
| Q1 FY2027 | ₹248 Cr | ₹18 Cr | 7.85% | 7.11% | ₹8.46 | 14.9x |
| Q4 FY2026 | ₹239 Cr | ₹16 Cr | 7.25% | 6.70% | ₹7.58 | 14.6x |
| Q3 FY2026 | ₹233 Cr | ₹15 Cr | 7.15% | 6.44% | ₹7.12 | 16.7x |
| Q2 FY2026 | ₹222 Cr | ₹18 Cr | 9.42% | 8.00% | ₹8.48 | 24.3x |
| Q1 FY2026 | ₹210 Cr | ₹18 Cr | 9.08% | 8.41% | ₹8.43 | 23.1x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.